BioSpace News Archive

The FDA has rejected Minerva Neurosciences’ treatment for negative symptoms in schizophrenia, noting a lack of data and other factors that led to the Complete Response Letter.

Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming TD Cowen 44th Annual Health Care Conference in Boston on Tuesday, March 5, 2024 at 2:10 p.m. Eastern Time.

Oragenics, Inc. announced the pricing of an underwritten public offering of 1,400,000 shares of its common stock at a public offering price of $1.50 per share, for gross proceeds of $2.1 million, before deducting underwriting discounts and offering expenses payable by the Company.

Oragenics, Inc., a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, announced that it intends to offer to sell shares of its common stock in lieu thereof) in an underwritten public offering.

ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) (“ME Therapeutics” or the “Company”), a preclinical stage biotechnology company working on

Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2023 before the market opens on March 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Sotera Health Company announced the launch of a secondary offering of 25,000,000 shares of its common stock, par value $0.01 per share.

MacroGenics, Inc. (Nasdaq: MGNX) today announced that the Company will release its financial results for the fourth quarter of 2023 after the market closes on Thursday, March 7, 2024.

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Decipher Prostate Genomic Classifier is the only gene expression test to receive a “Level 1B” evidence rating in the 2024 NCCN* Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a prognostic tool for the risk stratification of patients with localized prostate cancer.

Dynavax Technologies Corporation (Nasdaq: DVAX) today announced that the Company will present at TD Cowen’s 44th Annual Health Care Conference on Monday, March 4 at 10:30 a.m. ET.